Risk of venous thromboembolism with bevacizumab in cancer patients

JAMA. 2009 Apr 8;301(14):1435; author reply 1435-6. doi: 10.1001/jama.2009.441.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bevacizumab
  • Catheterization, Central Venous
  • Fluorouracil / adverse effects
  • Humans
  • Neoplasms / drug therapy
  • Risk
  • Venous Thromboembolism / etiology*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Bevacizumab
  • Fluorouracil